Russian scientists from the Laboratory of Cardiac Electrophysiology Research Institute experimental cardiology supported by the Russian Foundation basic research (RFBR) developed a unique a drug that can save a person from arrhythmia. it achievement is of great importance since cardiovascular diseases are currently the leading cause of death on Earth, while it is arrhythmia that kills the largest number patients. Arrhythmia affects about 2% of the world’s population, and in over 50 years old – up to 15%. Alas, the most effective modern drugs can only help in half the cases, and even then only if taken in the first 7 days after an attack heart rate. There are more effective drugs, but they are in 10-15% of cases lead to fatal complications. Thus, millions of people around the world are forced to accept life-threatening drugs or living with fear of death every day. The situation may be corrected by a new Russian drug called “Niferidil”, which has passed all the necessary tests since June 2014 year will begin to be sold as ampoules for injection. New cure can treat atrial fibrillation, which is the most common heart rhythm disturbance. Main acting niferidil substance is a compound 1-p-fluorophenyl-1-p-nitrobenzoylamine-2- (N-ethylperidyl-4) ethane hydrochloride. This substance is promising. class III antiarrhythmic drugs that fight arrhythmia due to the suppression of potassium currents. Still drugs Class III in a large percentage of cases caused life-threatening side effects. Russian niferidil – the first drug of class III with a minimum of harmful effects on the body. 
Photos from open sources The effectiveness of niferidil in a dose of up to 30 mcg / kg depending on the duration of the current episode atrial arrhythmias Unlike other similar drugs, niferidil in 2 times more effective and helps in 85-90% of cases, with side the effects of niferidil are found only in 1.2% of cases. By preliminary estimates, such drugs need 3 million Russian patients. Niferidil will initially be released in ampoule form, that is, it will need to be taken in the form of injections. This is not very convenient, especially considering that antiarrhythmic drugs must be taken daily. The developers promise that a more convenient option for use in the form of tablets will be ready for sale in a few years – subject to sufficient financing and successful trials. Be that as it may, even as injection of the Russian drug will help many patients, and through for several years, perhaps millions of Russians with arrhythmia can live a normal active life.
Life Russia
